Role of the Presenilin1mediated Cleavage of Ephrin B Proteins
Principal Investigator
Anastasios Georgakopoulos, PhD
Icahn School of Medicine at Mount Sinai
New York, NY, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$200,000
Active Dates
April 01, 2003 - March 31, 2005
Grant ID
A2003031
Summary
Alzheimer’s disease (AD) is a neurodegenerative disorder of the central nervous system (CNS). There are at least two forms of AD: the sporadic form, which inflicts most AD patients and usually occurs after the age of 65 or 70, and the familial form, which occurs at earlier stages and follows a more rapid progressive course than the sporadic disease. Familial AD (FAD) is caused by mutations in certain genes, including the amyloid precursor protein (APP) gene, presenilin-1 (PS1), and presenilin-2 (PS2). PS1 mutations are responsible for most cases of FAD. It was recently demonstrated that PS1 controls the γ-secretase-mediated cleavage of several type I transmembrane proteins like the APP, Notch, erbB4, CD44 and E-cadherin. EphrinB proteins are type I transmembrane proteins that are ligands for the ephrinB receptors (EphBs). Both proteins are expressed in the CNS and are also found at the neuronal synapses, where they play a very important role in the synaptic function affecting memory. The goal of this study is to investigate the role of PS1-dependent γ-secretase-like activity in the processing and function of ephrinB proteins.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD